Jump to Navigation
MDA | Muscular Dystrophy Association
  • About MDA
  • Advocacy
  • Publications
  • Media
Give Now.
Give online Give by mail Give by phone

Main menu

  • Home
  • Learn About Muscle Diseases
  • Help Through Services
  • Hope Through Research
  • Ways to Help MDA

Search form

Research News

[title]
DMD: Eteplirsen Shows Continued Benefit at 84 Weeks
June 19, 2013
Eteplirsen, an experimental exon-skipping drug designed to treat Duchenne muscular dystrophy (DMD) caused by specific mutations in the dystrophin gene, continues to show sustained benefit on walking
[title]
DMD Symptoms Show Up Early and Can Be Measured, Study Finds
June 19, 2013
Careful assessments of motor, cognitive and language function in very young children with Duchenne muscular dystrophy (DMD) show these children lag behind their age-matched peers well before obvious
[title]
ALS Briefs: New Findings About Three ALS-Associated Genes
June 13, 2013
Recent research in amyotrophic lateral sclerosis (ALS) includes findings involving the CRMP4, FUS and TDP43 genes. Rare variant in the CRMP4 gene is associated with ALS A study conducted in France
[title]
DMD: 'Permanent' Gene Repair Strategy Looks Good in Lab
June 11, 2013
Permanent repair of a faulty gene has long been a goal of researchers working to develop gene-based therapies. But many current gene modification strategies that have entered clinical trials have
[title]
Genzyme and MDA Provide Pompe Families with Free Testing
June 10, 2013
Pompe disease (acid maltase deficiency, or GAA deficiency) shares symptoms with several other disorders and, in the absence of specific testing, can sometimes be confused with these other conditions
[title]
MD Briefs: Registries Are Still Open
June 07, 2013
FSHD, MMD: Registry remains open The University of Rochester Medical Center in New York state would like to remind people with facioscapulohumeral muscular dystrophy (FSHD) or myotonic muscular
[title]
ALS Briefs: Disease Modifier, Growth Factors, Antioxidant Genes
June 06, 2013
Identification of the biological mechanisms that underlie amyotrophic lateral sclerosis (ALS) may provide scientists with important clues about the disease that may be used to identify biomarkers and
[title]
New Muscular Dystrophy Drugs Offer Hope
June 04, 2013
[title]
Study Suggests Sleep-Disordered Breathing Common in FA
June 04, 2013
Results from a study conducted in Australia show that a nighttime respiratory problem called obstructive sleep apnea occurs more frequently in people with Friedreich's ataxia (FA) than in the general
[title]
Exome Sequencing Links New Genes to Sporadic ALS
May 31, 2013
A team of researchers in the U.S. and Australia has shed new light on sporadic amyotrophic lateral sclerosis (ALS), finding that some people with the disorder have gene mutations that may be
[title]
MTM: MDA Funds Development of Myotubularin-Based Treatment
May 29, 2013
The Muscular Dystrophy Association has awarded $1,195,762 over two years to biotechnology company Valerion Therapeutics (formerly 4s3 Bioscience) for development of a treatment for myotubular
[title]
SBMA: Mixed Results in Study of Clenbuterol
May 29, 2013
A 20-person, open-label pilot trial conducted in Italy and designed to test the safety, tolerability and efficacy of clenbuterol in people with spinal-bulbar muscular atrophy (SBMA, or Kennedy
[title]
Moving Toward 'Next-Generation' Gene Therapy
May 22, 2013
Planning for the next generation of gene and stem cell therapies for muscular dystrophies — even as the first generation is still under development — was the theme of a joint symposium sponsored by
[title]
More Data Reported from Neuralstem's Phase 1 Stem Cell Trial in ALS
May 22, 2013
Recently announced data from a phase 1 clinical trial of NSI-566 neural stem cells in people with amyotrophic lateral sclerosis (ALS) show that a subset of trial participants had better outcomes than
[title]
New MDA/ALS Center Opens at LSU
May 20, 2013
The Muscular Dystrophy Association has designated the MDA clinic at Louisiana State University Health Sciences Center School of Medicine in New Orleans as an MDA/ALS center. This brings the total
[title]
FA: RG2833 Is Well-Tolerated and Increases Frataxin Gene Activity
May 17, 2013
Interim results from a phase 1 clinical trial of RG2833 in people with Friedreich’s ataxia (FA) show that the experimental drug is well-tolerated, and that it appears to increase the activity of the
[title]
Newborn Screening Recommended for Pompe Disease
May 17, 2013
The Discretionary Advisory Committee on Heritable Disorders in Newborns and Children (DACHDNC) today voted to add Pompe disease (acid maltase deficiency) to a list of diseases that it recommends
[title]
Trial Tests 'Master Regulator' in ALS
May 16, 2013
A phase 2 clinical trial to test the experimental drug GM604 in people with amyotrophic lateral sclerosis (ALS) has opened at two trial sites in the United States. Enrollment is expected to begin
[title]
Melatonin is Neuroprotective in ALS Mice
May 10, 2013
Melatonin, a naturally occurring hormone produced by the pineal gland, is best known for its role in regulating sleep. Now, results from a study supported in part by MDA show that treatment with the
[title]
DMD, BMD: Phase 3 Trial Opens for Stop Codon Read-Through Drug
May 08, 2013
A large-scale, multinational phase 3 trial of the experimental drug ataluren has opened its first trial site, in Cincinnati, Ohio. The trial is recruiting boys with Duchenne muscular dystrophy (DMD)
[title]
SMA: Trial Tests Antisense Therapy in Infants
May 07, 2013
A phase 2 clinical trial to test multiple doses of the experimental drug ISIS-SMNRx in infants with spinal muscular atrophy (SMA) has opened at four trial sites in the United States and Canada.
[title]
MTM Phone-Based 'Event' Study Now Open
May 03, 2013
The Myotubular Myopathy Event Study, a telephone-based survey, will gather information about MTM-associated events, such as emergency room visits, hospitalizations, medication reactions, and
[title]
UPDATE: ACE-031 Clinical Trials in Duchenne MD
May 02, 2013
Biopharmaceutical companies Acceleron Pharma and Shire announced April 21, 2011, that MDA-supported clinical trials of ACE-031 for Duchenne muscular dystrophy (DMD) have been halted. A phase 2, dose-
[title]
MDA Scientific Conference Blog: Playing in the Same Sandbox
April 25, 2013
[title]
MDA Scientific Conference Blog: We Need Each Other
April 25, 2013

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • next ›
  • last »
View All News

Research

  • Research News
  • Active Research Grants
  • Research Grants Programs
  • MDA Translational Research Program
  • Opportunities for Researchers
  • Annual Conference Series
  • Grants at a Glance — Winter 2013
  • MDA Research Contact
  • Helpful Links
  • Clinical Trials and Studies
  • Clinical Research Network Grant
  • Newborn Screening for Neuromuscular Diseases
  • MyoBlast Research Newsletter
MDA in Your Community


Quick Links

  • Tell Us About Your MDA Clinic
  • Become an MDA Advocate
  • Be a Summer Camp Volunteer
  • Sign Up for MDA News Updates
  • MDA's Muscle Shop

Give Now.

Ways To Help

  • Advocacy
  • Become a Volunteer
  • Donor Login
  • Legacy Gifts
  • MDA Programs
  • Matching Gifts

About MDA

  • Art Collection
  • Contact MDA
  • Become a Volunteer
  • Careers
  • FAQ
  • Media
  • What is MDA?

MDA.org

  • Find Support
  • Get Involved
  • Publications
  • Site Map
  • Muscle Shop

Connect with MDA

  • Facebook Twitter YouTube  

Muscular Dystrophy Association — USA
National Headquarters
3300 E. Sunrise Drive
Tucson, AZ 85718
(800) 572-1717

Privacy Policy | Terms of Use

©2013, Muscular Dystrophy Association Inc. All rights reserved.
 

Advertise